December 2, 2019

STADA announced in a press release that it would purchased part of the Biopharma pharmaceutical business.

This is one of the largest investments in pharmaceuticals and business in Ukraine in recent years.

The group acquires production facilities in Bila Tserkva.

Thus, Biopharma will become part of STADA, which, according to CEO Peter Goldschmidt, will be an important player in the Ukrainian pharmaceutical market with strong local production.

Biopharma shareholders retain their plasma processing business. According to Konstantin Efimenko, Managing Partner, the company will develop a chain of blood collection centers and expand on the international market.

Approval of the transaction in Ukraine is expected. They plan to complete it this month.

STADA Arzneimittel AG is a manufacturer of generic drugs and consumer health products with headquarters in Bad Vilbel (Germany). Products are sold in 120 countries. About 140 types of drugs are presented in Ukraine. In 2018, sales amounted to EUR 2,330.8 mln, and revenue - EUR 503.5 mln.

Biopharma is a Ukrainian company founded in the late 19th century. It develops probiotics and plasma-based drugs that it exports to over 36 countries. Annually produces about 20 million packages of drugs.

Join M&A Ukraine

Request membership to M&A Ukraine

  • Connect with members on M&A Ukraine who run, advise, finance, and acquire private companies
  • Find out about the latest Ukrainian M&A news, recent deals and historical M&A transactions with financials and exit multiples
  • Find new investments, partnership opportunities, funding, mergers and acquisitions deals in Ukraine